A Prospective, Open-label, Randomized Phase III Study to Evaluate the Efficacy of ZOMETA® (Zoledronic Acid) in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms .
Baseline, the first, second and third month
Li Zhang, Master
Cancer Center of Sun Yat-Sen University (CCSU)
China: Food and Drug Administration